Education
About Us
Working with TipRanks
Follow Us
Alaunos Therapeutics (TCRT)
NASDAQ:TCRT
Top Page
Alaunos Therapeutics
(NASDAQ:TCRT)
38Underperform
Alaunos Therapeutics (TCRT) vs. S&P 500 (SPY)
Market Cap
$2.47M
Dividend YieldN/A
Average Volume (3M)10.49K
Price to Earnings (P/E)―
Beta (1Y)1.89
Revenue Growth-60.00%
EPS Growth68.32%
CountryUS
Employees1
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.36
Shares Outstanding1,601,252
10 Day Avg. Volume11,929
30 Day Avg. Volume10,486
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)410.99
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alaunos Therapeutics Business Overview & Revenue Model
Company DescriptionAlaunos Therapeutics (TCRT) is a biotechnology company specializing in the development of innovative cell therapies for the treatment of cancer. The company focuses on leveraging its proprietary TCR-T cell therapy platform to target and eliminate cancer cells, aiming to provide effective solutions for patients with limited treatment options. Operating in the healthcare and biopharmaceutical sectors, Alaunos Therapeutics is committed to advancing the field of immunotherapy by developing cutting-edge treatments that harness the power of the immune system.
How the Company Makes MoneyAlaunos Therapeutics primarily generates revenue through the development and commercialization of its TCR-T cell therapy products. Its revenue model is centered around obtaining funding through research collaborations, partnerships, and potential licensing agreements with pharmaceutical companies interested in its proprietary technologies. The company may also pursue revenue through milestone payments and royalties from successful commercialization of its therapies in collaboration with partners. Additionally, Alaunos Therapeutics may receive grants and government funding to support its research and development efforts. However, as a clinical-stage company, it may currently rely on investment capital rather than substantial product sales for its financial needs.
Alaunos Therapeutics Financial Statement Overview
Summary
Alaunos Therapeutics shows signs of improvement in revenue and cash flow management in the TTM period, but persistent profitability issues and historical volatility in cash flows pose significant risks. The balance sheet remains under pressure due to low equity and ongoing net losses.Income Statement
The company has experienced significant revenue growth in recent periods, with a TTM revenue increase from previous annual figures. However, it continues to operate at a loss, highlighted by negative gross profit, EBIT, and net income margins, indicating ongoing challenges in achieving profitability.25
Negative
Balance Sheet
The company's balance sheet shows low leverage with no total debt reported in the TTM period, which is a positive sign. However, the equity ratio has decreased, and the return on equity remains negative due to ongoing net losses, indicating a weak financial position.30
Negative
Cash Flow
Cash flows have improved with significant positive operating and free cash flows in the TTM period, demonstrating better cash management. However, the historical trend shows volatility, and reliance on financing activities is evident, suggesting potential sustainability concerns.45
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 6.00K | 5.00K | 2.92M | 398.00K | 0.00 | 0.00 | Gross Profit |
| -238.00K | -4.80M | 163.00K | -342.00K | -1.13M | -629.00K | EBIT |
| -7.42M | -34.27M | -35.10M | -77.55M | -80.36M | 2.26M | EBITDA |
| -11.54M | -30.90M | -31.82M | -74.97M | -78.85M | -117.17M | Net Income Common Stockholders |
| -11.78M | -35.14M | -37.60M | -76.89M | -78.85M | -177.92M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 61.73M | 6.06M | 39.06M | 76.05M | 115.07M | 79.74M | Total Assets |
| 95.05M | 8.26M | 64.94M | 94.86M | 146.34M | 109.11M | Total Debt |
| 0.00 | 0.00 | 19.51M | 29.36M | 4.81M | 2.35M | Net Debt |
| -61.73M | -6.06M | -19.55M | -46.69M | -110.25M | -77.39M | Total Liabilities |
| 9.49M | 1.96M | 26.38M | 36.81M | 22.36M | 109.11M | Stockholders Equity |
| 85.56M | 6.31M | 38.55M | 58.06M | 123.98M | 95.01M |
| Cash Flow | Free Cash Flow | ||||
| 17.91M | -30.34M | -29.45M | -64.79M | -66.79M | -41.14M | Operating Cash Flow |
| 15.67M | -30.14M | -29.23M | -61.47M | -57.01M | -40.85M | Investing Cash Flow |
| 1.50M | 1.35M | -193.00K | -3.32M | -9.78M | -284.00K | Financing Cash Flow |
| -24.95M | -18.14M | 6.37M | 25.78M | 102.12M | 59.15M |
Alaunos Therapeutics Technical Analysis
Negative
1.50
Price Trends
1.69
Negative
1.92
Negative
3.37
Negative
Market Momentum
-0.05
Negative
41.15
Neutral
22.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRT, the sentiment is Negative. The current price of 1.5 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.69, and below the 200-day MA of 3.37, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 41.15 is Neutral, neither overbought nor oversold. The STOCH value of 22.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRT.
Alaunos Therapeutics Risk Analysis
Alaunos Therapeutics disclosed 58 risk factors in its most recent earnings report. Alaunos Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alaunos Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
48 Neutral | $1.28B | ― | -57.48% | ― | 13698.99% | 31.46% | |
46 Neutral | $3.63B | ― | -19.20% | ― | -89.95% | -123.71% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
42 Neutral | $110.00M | ― | -54.21% | ― | -78.55% | -0.92% | |
38 Underperform | $2.47M | ― | -141.73% | ― | -60.00% | 68.32% |
* Healthcare Sector Average
Performance Comparison
TCRT
Alaunos Therapeutics
1.48
-14.92
-90.98%
BLUE
Bluebird Bio
3.73
-22.87
-85.98%
FATE
Fate Therapeutics
0.94
-6.29
-87.00%
IOVA
Iovance Biotherapeutics
3.52
-10.69
-75.23%
ADAP
Adaptimmune Therapeutics
0.45
-1.01
-69.18%
CRSP
Crispr Therapeutics AG
41.99
-30.02
-41.69%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.